Updates on first- and second-generation antidepressants used in the treatment of traumatic brain injury-induced depression

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-07-20 DOI:10.1016/j.pnpbp.2025.111458

Nicla Tranchida , Francesca Inferrera , Salvatore Cuzzocrea , Marika Cordaro , Rosanna Di Paola

{"title":"Updates on first- and second-generation antidepressants used in the treatment of traumatic brain injury-induced depression","authors":"Nicla Tranchida , Francesca Inferrera , Salvatore Cuzzocrea , Marika Cordaro , Rosanna Di Paola","doi":"10.1016/j.pnpbp.2025.111458","DOIUrl":null,"url":null,"abstract":"<div><div>One of the leading causes of disability leading to depression and other neuropsychiatric complications is traumatic brain injury, especially among young people. Post-TBI depression is a common condition with a significant impact on quality of life, recovery, and rehabilitation. In the last years, the second-generation antidepressants SNRIs and SSRIs have been applied as treatments for depression in patients with TBI. Due to the more favorable side effect profiles, these agents are considered over first-generation antidepressants. While further studies are needed to identify specific mechanisms and interactions with drug-induced brain trauma effects, preliminary studies do suggest that second-generation antidepressants may be useful in treating post-TBI depression. This review focus on the benefits, challenges, and emerging scientific evidence regarding the use second-generation antidepressants in TBI patients.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"141 ","pages":"Article 111458"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S027858462500212X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

One of the leading causes of disability leading to depression and other neuropsychiatric complications is traumatic brain injury, especially among young people. Post-TBI depression is a common condition with a significant impact on quality of life, recovery, and rehabilitation. In the last years, the second-generation antidepressants SNRIs and SSRIs have been applied as treatments for depression in patients with TBI. Due to the more favorable side effect profiles, these agents are considered over first-generation antidepressants. While further studies are needed to identify specific mechanisms and interactions with drug-induced brain trauma effects, preliminary studies do suggest that second-generation antidepressants may be useful in treating post-TBI depression. This review focus on the benefits, challenges, and emerging scientific evidence regarding the use second-generation antidepressants in TBI patients.

查看原文本刊更多论文

第一代和第二代抗抑郁药用于治疗创伤性脑损伤引起的抑郁症的最新进展

创伤性脑损伤是导致抑郁症和其他神经精神并发症的主要原因之一，尤其是在年轻人中。脑外伤后抑郁是一种常见的情况，对生活质量、恢复和康复有重大影响。在过去的几年里，第二代抗抑郁药SNRIs和SSRIs被用于治疗TBI患者的抑郁症。由于更有利的副作用，这些药物被认为是第一代抗抑郁药。虽然需要进一步的研究来确定药物引起的脑外伤的具体机制和相互作用，但初步研究确实表明，第二代抗抑郁药可能对治疗创伤后抑郁症有用。这篇综述的重点是关于在TBI患者中使用第二代抗抑郁药的益处、挑战和新出现的科学证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.